The Life Sciences team advised Navitor Pharmaceuticals, LLC on Janssen Pharmaceuticals, Inc.’s acquisition of Anakuria Therapeutics, Inc.
Navitor is the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives.
Anakuria is a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 inhibitors. Anakuria’s lead Phase 1 ready program, AT-20494 provides Janssen with a first-in-class opportunity in autosomal dominant polycystic kidney disease, or ADPKD. This deal was facilitated by Johnson & Johnson Innovation.
Under the terms of the agreement, Janssen has acquired all outstanding shares of Anakuria, which is now a wholly owned subsidiary of Janssen.
The Goodwin team was led by Danielle Lauzon, Dan Hughes, Chris Guerin, and Will Ogden (Corporate); and included Kathleen Kean (Intellectual Property); Dan Karelitz and Leon Peschel (Tax); Sarah Bock (ERISA & Executive Compensation); Steven Tjoe (FDA); Paul Jin (Antitrust); and Caroline Galiatsos (Employment); with invaluable assistance from Coleen Doyle.
For more details, read the press release.